Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT00194740
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Docetaxel — DRUG
    60 mg/m2, IV, day 1 of each 21 day cycle
  • Vinorelbine — DRUG
    27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle
  • Filgrastim — DRUG
    5 µg/kg/day s.c., to be administered days 2-21 of each cycle.

Study Details

The two drugs used to treat metastatic breast cancer in this study may perform better when used together than when used separately. The use of another drug that prevents the most common side effect of the two-drug combination permits the delivery of both agents at closer to the "full" dose for either when used alone. We hypothesize that the two-drug combination used with G-CSF support will be more effective and less toxic than other standard regimens for the treatment of metastatic breast cancer.

Key Dates

Start date
Nov 30, 1997
Status verified
Dec 2007
Completion
Jun 30, 2007

Study Design

Enrollment
48 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Response to treatment [ Time Frame: Until disease progression ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Washington/Seattle Cancer Care AllianceSeattleWashington98109-1023-

Find similar trials in Seattle, WA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
University of Washington/Seattle Cancer Care Alliance· Seattle, WA

Related Studies